Diabetes Drug Avandia Suspected of Increasing Heart Attack and Death Risk
A new study to be published next month in the New England Journal of Medicine shows that patients taking Avandia (generic: rosiglitazone) for type 2 diabetes have a 43 percent higher risk of having a heart attack than those on other diabetes medications. Even worse was the finding that patients taking Avandia had a 64 percent higher chance of dying from cardiovascular causes than their counterparts not taking Avandia. The new study was an evaluation of 42 older studies which compared patients taking Avandia with others not using the drug. Of the almost 28,000 patients studied, 15,560 were taking Avandia.
Continue reading "Diabetes Drug Avandia Suspected of Increasing Heart Attack and Death Risk" »
